About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2024
2023
2022
2021
2020
14
Mar 2023
17:00 E.S.T.
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
Read more
08
Mar 2023
16:45 E.S.T.
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Read more
06
Mar 2023
16:30 E.S.T.
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
Read more
01
Mar 2023
16:30 E.S.T.
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
Read more
07
Feb 2023
17:32 E.S.T.
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
Read more
03
Feb 2023
09:41 E.S.T.
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
Read more
Prev
4
5
6
7
Next